Literature DB >> 3893343

Hypertension management in the Multiple Risk Factor Intervention Trial (MRFIT). Six-year intervention results for men in special intervention and usual care groups.

R H Grimm, J D Cohen, W M Smith, L Falvo-Gerard, J D Neaton.   

Abstract

The Multiple Risk Factor Intervention Trial was a large collaborative primary prevention trial designed to test the effects of lowering cardiovascular risk factors (ie, diastolic blood pressure [DBP], serum cholesterol, and cigarette smoking) on mortality rate from coronary heart disease in 12,866 high-risk men aged 35 to 57 years. Men were randomly assigned to either special intervention (SI) or usual care (UC) groups. Usual care men were referred to their regular source of medical care. Special intervention men were seen frequently and underwent intensive intervention initially followed by maintenance intervention in 22 different clinical centers. Hypertension intervention in SI men primarily consisted of a stepped-care pharmacologic approach designed to lower blood pressure (BP). After six years, 58.2% of SI men and 47.0% of UC men were given antihypertensive medication. In both study groups, mean systolic and diastolic BPs decreased from baseline; after six years, overall DBP was 3.2 mm Hg lower in SI men compared with UC men. In hypertensive men (DBP greater than or equal to 90 mm Hg or those taking antihypertensive medication at baseline), after six years, DBP was 4.4 mm Hg lower in the SI group compared with the UC group. Use of specific antihypertensive agents differed substantially between the two groups. Self-reported complaints while taking antihypertensive drugs were minimal in both groups. Weight loss was associated with BP lowering in both study groups, regardless of treatment status.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3893343

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  14 in total

1.  The relationship between preoperative and primary care blood pressure among veterans presenting from home for surgery: is there evidence for anesthesiologist-initiated blood pressure referral?

Authors:  Robert B Schonberger; Matthew M Burg; Natalie Holt; Carrie L Lukens; Feng Dai; Cynthia Brandt
Journal:  Anesth Analg       Date:  2011-11-10       Impact factor: 5.108

2.  Hypertension and non-insulin dependent diabetes.

Authors:  J S Yudkin
Journal:  BMJ       Date:  1991-09-28

Review 3.  Choosing the right beta-blocker. A guide to selection.

Authors:  J R Hampton
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

4.  Intermittent claudication should not be treated by surgery.

Authors:  M J Phillips; A R Cowan; C D Johnson
Journal:  Ann R Coll Surg Engl       Date:  1997-07       Impact factor: 1.891

5.  Evaluation of lipid metabolism during antihypertensive treatment with nicardipine sr.

Authors:  F Pasanisi; T Marotta; L A Ferrara; O Russo; M Mancini
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 6.  Goals of antihypertensive therapy.

Authors:  G E McVeigh; J Flack; R Grimm
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

Review 7.  Lipids, lipoproteins, and coronary heart disease: implications for antihypertensive therapy.

Authors:  M D Feher; D J Betteridge
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

8.  Trends in Prehypertension and Hypertension Risk Factors in US Adults: 1999-2012.

Authors:  John N Booth; Jiexiang Li; Lu Zhang; Liwei Chen; Paul Muntner; Brent Egan
Journal:  Hypertension       Date:  2017-06-12       Impact factor: 10.190

Review 9.  Emerging insights in the first-step use of antihypertensive combination therapy.

Authors:  Keith Norris; Joel M Neutel
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-12       Impact factor: 3.738

10.  Balancing Model Performance and Simplicity to Predict Postoperative Primary Care Blood Pressure Elevation.

Authors:  Robert B Schonberger; Feng Dai; Cynthia A Brandt; Matthew M Burg
Journal:  Anesth Analg       Date:  2015-09       Impact factor: 6.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.